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Background and purpose: It is well known that inﬂammation inﬂuence chronic subdural hematoma (CSDH) for-
mation to a large extent. Atorvastatin has pleiotropic effects on restraining inﬂammation and promoting angio-
genesis besides its cholesterol-lowering function. Hence, atorvastatin may induce anti-inﬂammation effects and
facilitate therapeutic effects for subdural hematoma (SDH).
Methods: Adult male Wistar rats were subjected to SDH and successful establishment of SDH was conﬁrmed by
magnetic resonance imaging (MRI). The treatment was initiated 6 hours after SDH induction. For the treatment,
rats suffering SDH were randomly divided into saline group (the control group, rats were treated by saline, n =
29) and atorvastatin group (rats were treated by atorvastatin, 3 mg/kg/day, n=30). The volume of lesion before
treatment as well as on day 2 and day 7 after initial treatment wasmeasured byMRI, respectively. The behaviors
before SDH induction and on the days 1, 3, 5 and 7 after the initial treatment were dynamically evaluated. Gene
expression, cytokine secretion and the number of neutrophilic granulocyte and vascular density were measured
in both neomembrane and SDH lesion on the day 2 and day 7 after the initial treatment.
Results: It was found that the SDH rats treated by atorvastatin had a better behavior recovery compared to the ones
treated by saline (p b 0.05). By virtue ofMRI scanning, it was revealed that SDH volumeswere eliminated at a high
speed by administration of atorvastatin than that of saline. With the help of the microscopic examination in the
neomembrane, it was detected that the density of CD31+neovasculars in the atorvastatin groupwas signiﬁcantly
higher than that in the saline group and the number of neutrophilic granulocyte in the atorvastatin group is less
than that in the saline group. In comparison with saline treatment, the atorvastatin treatment did not change
IL-10 expression and secretion, but it signiﬁcantly decreased TNF-α and IL-6 level aswell as VEGF gene expression.
Conclusions: Atorvastatin treatment may eliminate SDH and improve the neural function of the rats through its
anti-inﬂammatory effects. Hence, it indicated that statin induced inﬂammatory modulation might play a signiﬁ-
cant role in rats’ SDH elimination and the functional recovery.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).nce Foundation of China (grant
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Generally, subdural hematoma (SDH) could be classiﬁed into acute,
sub-acute and chronic subtypes based on the time between injury and
appearance of hematomas. Acute SDH (ASDH) refers to the hematomas
which formwithin 3 days after injury, while chronic SDH (CSDH) is con-
sidered to be the hematomas generated 3 weeks after injury. Mostly,
acute traumatic SDH, whose mortality reaches up to 50%, are treated
by an emergency operation [1–3]. However, CSDH is mainly found in
the aged and resulted from a cephalic trauma or indirect head injury.
Up to now, detailedmechanisms of CSDHhave not been clearly clariﬁed
and therapeutics for CSDH have been controversial [4]. Some studiesthe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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reaction [5–7]. Recent reports have revealed that inﬂammatory factors
in hematoma ﬂuid of CSDH patients are highly elevated [8]. It was
shown that administration of dexamethasone which acts as a potent
anti-inﬂammatory drug [9] successfully cures CSDH, the hypothesis
that localized chronic inﬂammatory reaction participates in formation
of CSDH is reasonable. However, it is worthmentioning that dexameth-
asone has many side effects including insomnia, increased weight, agi-
tation, acne, thrush, nausea, vomiting and so on, which inﬂuence its
clinical use [10].
As cholesterol-lowering drugs, statins and HMG-CoA reductase in-
hibitors are widely used to prevent and treat coronary artery disease
[11]. It should be noted that statins are pleiotropic medicines which in-
duce angiogenesis and have anti-oxidation and inﬂammatory modula-
tion effects. A series of in vitro and in vivo experiments have conﬁrmed
that statins have ability to suppress inﬂammation,which is independent
of their potent function on blood lipid reduction [12–14]. To verify that
inﬂammation involved in the formation and elimination of CSDH, we
studied effects of atorvastatin on regulating inﬂammatory cytokines in-
side SDH and changes in the volumes of SDH based on the rat model of
SDH established previously [15].
2. Materials and methods
2.1. Animal model
Eighty adult male Wistar rats (350–400 g, obtained from Military
Medical Academy of China) were housed in animal facility of Tianjin
Medical University General Hospital. All animal procedures were per-
formed in accordance with the institutional animal care guidelines ap-
proved by Chinese Small Animal Protection Association.
2.1.1. SDH models
The ratmodels of SDHwere established according to the procedures
which had been published before with a little modiﬁcation [15]. The
detailed procedures were shown as follows. First of all, to expose its
coronal and sagittal suture, the rat was positioned in a stereotaxic
frame (Stoelting, Wood Dale, IL) after satisfactorily intraperitoneal
anesthetizationwith 10%of chloral hydrate solution. Then, a small sphe-
noid burr hole (0.9 mm in diameter) was performed by using a sphe-
noid drill on the left coronal suture whose lateral distance to the
sagittal suture was 3 mm. Next, endocranium of the rat was scuffed
with a small hooked needle (with a diameter of 0.3 mm) under the
microscope. Then, 300 μl autologous venous blood collected from
angular vein of the rat was injected into its subdural space at a rate of
50 ml/min by using a 20-gauge Venﬂon catheter with a tapered tip
(BD Venﬂon, Helsingborg, Sweden).
2.1.2. Magnetic resonance imaging (MRI) and criteria for selection
Two hours after SDH induction, the magnetic resonance imaging
(MRI) (GE3.0 T) was applied to demonstrate whether SDHwas success-
fully established or not. Meanwhile, volume of the lesionwasmeasured.
The rat was ﬁxed on the coil (3 T, Shanghai Chengguang Technology Co.
Ltd CG-MUC19-H300-AG) and positioned into the MRI (GE3.0 T). MRI
session startedwith T2WI along the coronal view of the rat’s headwith-
out contrast injection, with 1-mm slice thickness. Inclusion and exclu-
sion of SDH rats were based on results of MRI scanning. Speciﬁcally,
with respect to the exclusion of SDHmodel, rats that failed in induction
of the SDH, SDH rats which had cortex contusion or laceration as well as
the ones suffered severe edema around the hematoma were excluded.
In typical SDH models, hypointensity hematoma and cortex ischemia
areas could be observed between skull and cortex in the prophase
after the induction of SDH models. However, cortex contusion, lacera-
tion and severe edema around the hematoma could not be observed.
In this study, we successfully established 59 out of 80 SDH rat models,
with a successful rate of 73.75%.2.1.3. Experimental groups
SDHratswere randomly divided into 2 groups. In detail, 30 ratswere
included in the atorvastatin group (3 mg/kg/day, Pﬁzer, USA) and 29 in
the saline group (the control group). The therapy was carried out
through intragastric tubes 6 hours after the induction of SDH and was
daily continued in a 7-day period. Neurological functional outcome
was detected dynamically on the 1st, 3rd, 5th and 7th days after the ini-
tial treatment. The change in the volumes of hematoma was assayed on
the 2nd and 7th days after the treatment by using MRI and calculated
via the Volume Viewer 4.3 (GE Healthcare, USA).
2.2. Histological assessment and tissue extraction
Ratswere sacriﬁced on the 2nd (n= 4/group) and 7th (n= 4/group)
days after the treatment. The rats were perfused by 0.9% NaCl and then
euthanized.
2.2.1. Brain tissue dissection
The cranium (except for the basilar region) was removed to expose
the whole brain. In order to delineate the surface of the hematoma, this
procedure was imaged by a high-resolution camera. Along an artiﬁcial
line that was 3 mm posterior to the burr hole and perpendicular to
the sagittal suture, the whole brain including basal bone was divided
into two parts which were approximately equal. Initial procedures of
tissue extraction for each certain assessment were the same.
2.2.2. Hematoxylin and eosin (H&E) staining
Firstly, the dura was ﬁxed in place by inserting 3 stylets of 25G
needles into the cortex before the brain was immersed in 4% parafor-
maldehyde for 48 hours at room temperature since it was critical to
keep the intact dura in place over a hematoma for subsequent histo-
logical examination. Then, the brain tissue was selected and cut into a
10-mmblock. Next, the blockwas dehydratedwith a graded ethanol se-
ries, cleared in dimethylbenzene and then embedded in parafﬁn.Mean-
while, the 10-mm coronal block was further cut into 0.5 mm sections
where H&E staining was performed according to standard procedures.
2.3. Immunohistochemical staining and quantiﬁcation
The brain tissue blocks were embedded in OCT medium (Sakura
Finetek USA. Inc.) and then cut into 10 μm sections displayed in slides.
In consideration of immunohistochemical staining, the slides were
ﬁrst treated by 0.3% H2O2 (20 min at room temperature) to quench en-
dogenous peroxidase activity. Next, they were incubated with 5% bo-
vine serum albumin to block nonspeciﬁc staining (30 min at room
temperature) and then incubated overnight at 4 °Cwith amousemono-
clonal antibody against CD31 (an endothelial cell marker, 1/200 dilu-
tion, Abcam ab64543), At the same time, the treated slides were
refrigerated at 4 °C overnight, which was followed by 30-min incuba-
tion with HRP-conjugated streptavidin (Zymed Laboratories, South
San Francisco, CA) at 37 °C. The antibody binding was visualized by
3,3-diaminobenzidine tetrahydrochloride, and the slides were counter-
stained with the help of Mayer’s hematoxylin. Similarly, negative con-
trols were processed without the primary antibody.
In addition, brain parafﬁn blocks were also obtained and then cut
into 6 μm sections displayed in slides. After deparafﬁnization and
redehydration, nonspeciﬁc endogenous peroxidase activitywas blocked
by treating sectionswith 3% hydrogen peroxide inmethanol for 30min.
Antigen was recovered by boiling the sections for 10 min in 10 mM
citrate buffer (pH 6.0). Nonspeciﬁc binding was blocked with 1% non-
immune serum in PBS for 30 min. The sections were then incubated
with rabbit polyclonal antibody against myeloperoxidase (1/100
dilution, Abcam ab9535) overnight at 4 °C. They were then washed
with PBS, incubated with a biotinylated anti-rabbit IgG (1:100, Santa
Cruz Biotechnology) for 2 hours at 37 °C, then washed and incubated
with an avidin peroxidase conjugate solution (1:100, Santa Cruz
Table 1
Neurologic severity scores (NSS).
Motor test points
Raising the rat by the tail 3
1 Flexion of forelimb
1 Flexion of hindlimb
1 Head moved more than 10° to the vertical axis within 30 seconds
Walking on the ﬂoor (normal = 0;maximum = 3) 3
0 Normal walk
1 Inability to walk straight
2 Circling toward the paretic side
3 Falling down to the paretic side
Beam balance tests (normal = 0;maximum = 6) 6
0 Balances with steady posture
1 Grasps side of beam
2 Hugs the beam and one limb falls down from the beam
3 Hugs the beam and two limbs fall down from the beam, or spins on beam
(N30 seconds)
4 Attempts to balance on the beam but falls off (N20 seconds)
5 Attempts to balance on the beam but falls off (N10 seconds)
6 Falls off: No attempt to balance or hang on to the beam (b10 seconds)
Reﬂexes absence 2
1 Pinna reﬂex (a head shake when touching the auditory meatus)
1 Corneal reﬂex (an eye blink when lightly touching the cornea
with cotton)
Maximum points 14
We performed three independent measurements on eight samples per group.
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aminobenzidine for 5 min. Negative controls were similarly processed,
but without the primary antibody.
In accordancewith the previousmethod [15], CD31+ cells and neu-
trophilic granulocytes were counted. Brieﬂy, ﬁve areas (four corners
and one central area) on each slide were chosen to count high density
of CD31+ (an endothelial cell marker) staining and neutrophilic
granulocytes under 100× magniﬁcation. In detail, endothelial cells or
their clusters thatwere stained positive for CD31 aswell as neutrophilic
granulocytes were counted under 400×magniﬁcation by two indepen-
dent investigators who were blinded to the treatment of the animals in
each chosen area.
2.4. Sample collection for real-time PCR and ELISA assay
Brain tissue with intact dura and hematoma was preserved in a
freezer at−80 °C for total RNA and protein extraction. The front part
of brain tissue with intact dura and hematoma preserved in the freezer
where the temperature was −80 °C was processed for PCR or ELISA
assay.
2.5. RT-PCR
The total RNA was isolated by using a Tissue Total RNA Extraction
Reagent (GenePharma, Hi-Tech Park, Shanghai, China) in accordance
with the manufacture’s direction. A real-time polymerase-chase reac-
tion (RT-PCR) was performed under the condition that RT-PCR Kit
(GenePharma, Hi-Tech Park, Shanghai, China) was utilized. ACTB was
used as an internal control. For primers, they included TNF-α: 5′-CACC
ACGCTCTTCTGTCTACTG-3′ and 5′-GCTACGGGCTTGTCACTCG-3′; IL-6:
5′-TGGAGTTCCGTTTCTACCTGG-3′ and 5′-AATGACTCTGGCTTTGTCTT
TCT-3′; IL-10: 5′-AGGCAGTGGAGCAGGTGAA-3′ and 5′-ACGTAGGCTT
CTATGCAGTTGA-3′; VEGF: 5′-GAGCAGGAGCCGAAGCC-3′ and 5′-GA
GCCCAGAAGTTGGACGA-3′; ACTB: 5′-GAAGTACCCCATTGAACACGG-3′
and 5′-TGGGTCATCTTTTCACGGTTG-3′. The condition under which
PCRwas implementedwas that the temperaturewas 95 °C and duration
was 3 min followed by 40 cycles at 95 °C for 15 seconds and 62 °C for
40 seconds. We performed three independent measurements on six
samples for each group.
2.6. ELISA assay for inﬂammation-related cytokines, the blood counting,
clotting functions and lipid assay
Three milliliters of blood was collected from angular vein of each
SDH rat on the 2nd (n = 8/group) and 7th (n = 8/group) days after
the initial treatment. Then, 1 ml of the blood was stored in a coagulant
tube and its serum was transferred into freezing tubes and kept at
−80 °C after centrifugation at 3000 rpm for 10 min. At the same time,
the left blood was stored in EDTAK2 anticoagulant tubes (0.5 ml) and
sodium citrate anticoagulant tubes (1.5 ml), respectively. Next, they
were sent to a clinical laboratory for blood counting (0.5 ml) and
clotting functions assay (1.5 ml) by an automatic blood analyzer (XT-
1800i Sysmex Corporation Japan) and a Thrombosis/Hemostasis Ana-
lyzer (CA-1500 Sysmex Corporation Japan), respectively. The pieces of
the neomembrane, which were taken out from the brain and stored at
−80 °C, were micro-ground. After being dissolved with 0.01 mol/L
PBS in a geometric proportion and mixed thoroughly, they were centri-
fuged at 5000 rpm for 5 min to separate supernatant ﬂuid. Then, the
blood serum and the supernatant ﬂuid of the SDH brain neomembrane
were used to measure the cytokines related to angiogenesis (TNF-α, IL-
6 and IL-10) according to the manufacture’s directions and with the
help of commercial ELISA kits (R&D Systems, USA). For ELISA, we per-
formed three independent measurements on eight samples in each
group. On the other hand, eight samples would be applied to the
blood counting and clotting functions assay for each group.By using the CardioChek P●A analyzer and total cholesterol and
triglycerides check strips (Polymer 285 Technology System, Inc.,
Indianapolis, IN) according to the manufacturer’s instructions, level of
blood lipids was measured 7 days after the treatment in both groups.
Fifteen microliters of blood was collected from vein of rats’ tails. The
data are presented by taking mg/dl as a unit.2.7. Neurological behavioral tests
Neurological Severity Scores (NSS) functional test was performed
before induction of SDH models and repeated on the 1st, 3rd, 5th and
7th days after the initial treatment. Speciﬁc procedures were based on
previous studies [16] and shown in Table 1. All testers werewell trained
and blinded to assignments of the experimental treatment.2.8. Statistical analysis
All data were analyzed by using SPSS (V16.0; SPSS, Inc., Chicago, IL)
and expressed as means ± SEM. To analyze the volume of the hemato-
ma, MVD in the neomembrane, expression of factors related to neovas-
cularization and inﬂammation in peripheral blood and neomembrane,
as well as outcomes of behavioral tests, one-way analysis of variance
(ANOVA) with a post hoc Bonferroni test was used. A paired Student’s
T test was adopted to analyze indexes at different time points in the
same group. In addition, Pearson’s correlation coefﬁcient was utilized
to examine the relationship between neomembrane neovascularization
and the change in the volume of hematoma. A p value thatwas less than
0.05 was considered to be statistically signiﬁcant.3. Results
In typical SDH models, the hypointensity hematoma and cortex is-
chemia areas could be observed between the skull and cortex in thepro-
phase after the induction of SDH models. As hematoma was absorbed
gradually and neomembrane was formed, hyperintense areas circulat-
ing the hematoma appeared and the volume of the hematoma de-
creased as time went on (Fig. 1A–D).
Fig. 1. Images ofMRI. TheMRI images obtained on the 2nd and the 7th days after the saline
treatment (A and C) and the atorvastatin treatment (B and D). “E” represents the changes
in the volume of the hematomas between the saline group and the atorvastatin group.
# indicates the change in the volume between the 2nd and 7th days after the initial treat-
ment wasmarkedly different (p b 0.001, Paired-Samples T Test). * stands for a statistically
signiﬁcant difference between the two groups (p = 0.037, one-way ANOVA).
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Fig. 1A–D showed MRI measurement 2 and 7 days after SDH in ani-
mals treated by saline (A and C) and atorvastatin (B and D). We found
that a time-dependent decreasing tendency appeared in the volumes
of hematomas in both groups. There was no signiﬁcant difference be-
tween the two groups 2 days after the treatment (257.125 ± 24.52 μl
vs 262.25 ± 24.53 μl, p N 0.05, one-way ANOVA). The volumes of
the SDH animals treated by atorvastatin were signiﬁcantly decreased
7 days after treatment (113.375 ± 19.50 μl) in comparison with SDH
animals accepting treatment of saline (137 ± 18.85 μl, p b 0.05,
Fig. 1E).
This indicated that the shrinkage of SDH in the rats was time depen-
dent but a more signiﬁcant shrinkage was induced by atorvastatin
treatment.Fig. 2. Changes in Neurological Severity Scores (NSS). We performed three independent
measurements on eight samples for each group. * represents a statistically signiﬁcant dis-
tinction between the two groups (p = 0.014 and p = 0.003 on the 5th and the 7th days
after the treatment respectively, one-way ANOVA).3.2. Atorvastatin treatment improved neurological outcomes after SDH
On the one hand, all rats with SDH had severe unilateral sensorimo-
tor deﬁcits. On the other hand, a decreased tendency in the mNSS wasrevealed after the treatment in both groups. However, atorvastatin in-
duced a signiﬁcant decrease in the mNSS on the 5th and 7th days after
the treatment compared with the animals treated by saline, which indi-
cated that the neurological function was apparently improved by ator-
vastatin treatment (Fig. 2).
3.3. Atorvastatin increased the microvessel density (MVD) of
the neomembrane
An increasedMVD stainedbyCD31was induced in the neomembrane
of SDH in both groups. However, the increasing degree of the MVD was
not signiﬁcant between the two groups on the 2nd day after the treat-
ment (10.63 ± 1.13 vs 9.75 ± 0.55, p N 0.05, one-way ANOVA). On the
7th day after the treatment, an apparent increasing in the MVD in the
neomembrane was observed in the atorvastatin group compared with
the saline group (67.13 ± 2.77 vs 51.13 ± 1.66, p b 0.05, n = 8, one-
way ANOVA) (Fig. 3F). On the 7th day after the treatment, it was con-
ﬁrmed that there was a signiﬁcant association between the MVD in
the neomembrane and the changes in volume of the hematoma in
both groups. The coefﬁcients were 0.731 in the saline group and the
atorvastatin group (p b 0.05, Pearson’s correlation coefﬁcient). These
suggested that the intensity of CD31 expression was positively related
to absorption of the SDH. The atorvastatin induced more MVD marked
by CD31 along with a signiﬁcant shrinkage of the SDH.
3.4. Atorvastatin decreased the neutrophilic granulocytes in neomembrane
As progression of inﬂammation, increased neutrophilic granulocytes
were induced in the neomembrane of SDH in both groups. However, on
the 7th day after the treatment, an apparent decreasing in the number
of neutrophilic granulocytes in the neomembrane was observed in the
atorvastatin group compared with the saline group (56.5 ± 1.76 vs
45.1± 2.58, p b 0.05, n=8, one-way ANOVA) (Fig. 4F). The atorvastat-
in decreases the number of neutrophilic granulocytes along with a sig-
niﬁcant shrinkage of the SDH.
3.5. Atorvastatin induced signiﬁcant anti-inﬂammatory effects and
decreased TNF-α and IL-6 cytokines in brain tissue after SDH instead of in
the circulating blood
To generally observe the changes in hematomas and neomembrane,
Fig. 5 showed there was a smaller amount of hematoma left in the
Fig. 3.MVD in themembrane of hematoma. The IH staining images of CD31 in the saline group (A and C) and the atorvastatin group (B and D) taken on the 2nd and the 7th days after the
treatment. Arrows indicate the CD31+ cells. * represents the statistically signiﬁcant distinction between the two groups (p= 0.004, one-way ANOVA) and E refers to CD31 staining of the
opposite side of trauma.
92 T. Li et al. / Journal of the Neurological Sciences 341 (2014) 88–96atorvastatin group or the saline group on the 7th day, but the
neomembrane became thicker compared with that on the 2nd day.
To test the underling mechanisms which were related to the situa-
tion that atorvastatin induced decrease in the volume of hematoma
after SDH, the inﬂammatory factors secretion (TNF-α and IL-6 and IL-
10) were measured by ELISA assay. As a result, no notable change was
detected in the level of the inﬂammation-related cytokines (TNF-α, IL-
6 and IL-10) in the peripheral blood between the 2nd day and 7th dayFig. 4. Neutrophilic granulocytes in the membrane of hematoma. The IH staining images of neu
taken on the 2nd and the 7th days after the treatment. * represents the statistically signiﬁcant di
granulocytes staining of the opposite side of trauma.after SDH in both groups. Furthermore, there was no diversity in these
cytokines in the peripheral blood between the two groups either on
the 2nd day or the 7th day after the treatment (Table 2). However, it
was found the TNF-α and IL-6 level in the damaged brain tissue of
neomembrane was signiﬁcantly decreased on the 7th day, while the
level of IL-10 of the brain neomembrane did not show signiﬁcant differ-
ence between the two groups (Fig. 6). The results indicated that SDH
contained several inﬂammation-related cytokines, and the atorvastatintrophilic granulocytes in the saline group (A and C) and the atorvastatin group (B and D)
stinction between the two groups (p= 0.02, one-way ANOVA) and E refers to neutrophilic
Fig. 5.Morphological changes in subdural hematomas. The HE staining sections from the saline group (A1 and C1) and the atorvastatin group (B1 and D1) (400×). The bar rep-
resents 25 μm. The HE staining sections of the saline group (A2 and C2) and the atorvastatin group (B2 and D2) (200×). Arrows indicate the neomembrane obtained on the 2nd
day after the treatment and arrows represent the neomembrane obtained at the 7th day post-treatment. The bar represents 50 μm. The images of the hematomas of the SDH rats
in the saline group (A3 and C3) and the atorvastatin group (B3 and D3).
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regulate the IL-10 expression in the brain neomembrane compared to
the saline treatment.
3.6. Atorvastatin induced the mRNA expression of the inﬂammation and
angiogenesis-related cytokines in SDH
To test whether atorvastatin regulated inﬂammatory factor gene ex-
pression, the total RNA was extracted from the neomembrane of the
SDH on the 2nd day and the 7th day after the treatment. Then, mRNA
abundances of the inﬂammation-related cytokines (TNF-α, IL-6 and
IL-10) and the angiogenesis-related cytokines (VEGF) in these
neomembrane were semi-quantitatively measured by using RT-PCR.
In consequence, it was showed that the changes in the mRNA amount
of all inﬂammatory cytokines were consistent with corresponding pro-
teins measured by virtue of ELISA. Besides, it was indicated that the
mRNA amount of TNF-α and IL-6 showed a descending tendency withTable 2
ELISA changes of factors in peripheral blood.
Control group Experimental group
2 day 7 day 2 day 7 day
TNF-α
(ng/L)
36.8 ± 5.57 37.43 ± 4.82 34.97 ± 4.82 36.52 ± 2.49
IL-6
(ng/L)
21.98 ± 1.86 22.31 ± 2.32 23.18 ± 2.27 21.01 ± 1.71
IL-10
(pg/ml)
29.28 ± 4.81 29.61 ± 2.9 31.17 ± 4.15 30.56 ± 4.19
The levels of the cytokines in the peripheral blood of the SDH rats receiving atorva-
statin or saline remained stable between the 2nd day and 7th day after treatment
initiation(p N 0.05, one-way ANOVA). Furthermore, the different treatment did not in-
duce a diversity change in the levels of the cytokines in the peripheral blood at the
same time points (p N 0.05 Paired-Samples T Test). We performed three independent
measurements on eight samples per group. Eight samples were included in each group.time in both groups and such a tendency wasmore obvious in the ator-
vastatin group. In addition, comparedwith the saline group, the atorva-
statin group also had signiﬁcantly decrease in TNF-α and IL-6 gene
expression 7 days after the treatment (p b 0.05, n = 6, one-way
ANOVA). However, there was no signiﬁcant difference in IL-10 gene ex-
pression between the two groups. Besides, the atorvastatin group also
had signiﬁcantly decrease in VEGF gene expression 7 days after the
treatment (p b 0.05, n = 6, one-way ANOVA), while the saline group
had an adverse change (Fig. 6.).
3.7. Atorvastatin did not change the blood counting, functions of blood
clotting or blood lipids
To observe effects of atorvastatin and inﬂammatory reaction of the
peripheral blood, both the blood counting and functions of blood
clotting were measured. On the basis of Table 3, it was revealed that
the blood counting and functions of blood clotting did not signiﬁcantly
change in the SDH rats when the atorvastatin treatment was used com-
paredwith the saline treatment. In addition, the detected lowest level of
the total cholesterol check stripswas 100 mg/dl.We found that the total
cholesterol level of both groups was less than 100 mg/dl. Triglyceride
was measured 7 days after the treatment (atorvastatin treatment:
72.1 ± 4.3 mg/dl; the saline group: 76.8 ± 4.1 mg/dl). There was no
signiﬁcant difference in the total level of cholesterol and triglyceride
between the two groups (p N 0.05, one-way ANOVA).
4. Discussion
Themechanisms of formation of CSDHhave been explored for sever-
al decades, but the detailedmechanism still needs to be fully elucidated.
Some researchers have advocated that CSDH is resulted from repeated
bleeding of nascent capsule [17,18]. Furthermore, it has shown that
there is an imbalanced regulation of plasminogen activator in hemato-
ma cavity, which disturbs the ﬁbrinolysis and thrombomodulin
Fig. 6.Expression of the inﬂammation cytokines and theirmRNAdetected by RT-PCRandELISA.Weperformed three independentmeasurements on eight samples (ELISA) and six samples
(PCR) for each group. # represents a statistically signiﬁcant distinction in the same group at different days (p b 0.05 Paired-Samples T Test). In addition, * represents a statistically signif-
icant distinction between the two groups (p b 0.05, one-way ANOVA).
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shrinkage speed of rats’ SDH is associated with enhanced angiogenesis
to a large extent [15]. Furthermore, in accordancewithmany clinical pa-
thology studies, it can be found that rich and disordered vessels are de-
veloped in the neomembrane of hematomas and form a number of
sinusoidal vessels with high permeability and fragility [8,23–26]. It
seems that angiogenesis plays a key role in both the formation and elim-
ination of CSDH. However, a high inﬂammatory reaction level has been
detected in the liquid of the CSDHwith apparent increase in TNF-α and
IL-6 [8] and ﬂuctuation of IL-10 [27]. The inﬂammatory reaction could
change osmotic pressure of hematoma liquid, which has impacts on an-
giogenesis by modifying maturation of vessels [28]. Statins have been
shown to have pleiotropic effects including anti-inﬂammation, neuro-
protection and angiogenesis regulation [29–31]. Since we have per-
formed researches on angiogenesis in SDH rats in another study (data
not shown), this research focused on inspecting both the role of inﬂam-
matory cytokines in the formation and elimination of SDH and the im-
pact of the statin on this effect.
According to our study, it was conﬁrmed that there were plenty of
inﬂammatory cytokines (TNF-α, IL-10, IL-6) in the SDH in vivo with a
consistent change in both protein and mRNA levels, while there was
not a notable change in inﬂammation in the circulating peripheral
blood. At the same time, it was revealed that a signiﬁcant shrinkage of
the SDH induced by atorvastatin was accompanied by the levelTable 3
Routine analysis of blood and functions of blood clotting.
Control group
2 day 7
Number of white cells (*109/L) 12.28 ± 0.53 1
Number of red cells (*1012/L) 7.04 ± 0.42 6
Number of platelets (*109/L) 721.88 ± 39.18 7
Prothrombin time (seconds) 10.63 ± 0.54 9
Fibrinogen (g/L) 2.64 ± 0.31 2
Theblood counting and coagulation function of the SDH rats receiving atorvastatin or saline rem
ANOVA). Furthermore, the different treatment did not induce a diversity change in these items
included in each group.modulation of these inﬂammatory cytokines and the decreasing
number of neutrophilic granulocytes. Both the pro-inﬂammatory cyto-
kine (TNF-α) and the dual role cytokine (IL-6) were down-regulated
by the atorvastatin treatment, while the anti-inﬂammatory cytokine
(IL-10) maintained constant.
TNF-α, a cytokine produced by activated macrophages in response
to pathogens and other injurious stimuli, was necessary and sufﬁcient
formediation of local and systemic inﬂammation [32]. IL-6was a potent
pleiotropic Th2 cytokine that regulated immune defense response and
played a dual role in pro-inﬂammatory and anti-inﬂammatory re-
sponses. Release of IL-6 was triggered by tissue damage or infection.
IL-6 played a key role in the transition from an acute phase to a chronic
one of the inﬂammatory process [33,34]. Though the function of IL-6
was a cytokine with a dual function, a signiﬁcant increase in IL-6 has
been conﬁrmed in published clinical literatures [8,26] and signiﬁcant
atorvastatin-inducing inhibition of IL-6 was correlatedwith the increas-
ing speed of hematoma shrinkage in SDHmodels. It indicated that TNF-
α and IL-6might play a pro-inﬂammatory role in the formation of CSDH,
while the inhibition of TNF-a and IL-6 contributed to eliminating the he-
matoma. IL-10 not only acted as an anti-inﬂammatory cytokine released
by monocytes and macrophages but also suppressed production of in-
ﬂammatory cytokines by monocytes [35,36]. Increasing level of IL-10
was related to less recurrence of CSDH [8]. Although the level of IL-10
was not increased signiﬁcantly by application of atorvastatin in ourExperimental group
day 2 day 7 day
2.83 ± 0.93 11.79 ± 1.15 10.67 ± 0.66
.95 ± 0.28 7.32 ± 1.06 6.78 ± 0.31
65.87 ± 59.51 717.13 ± 42.31 651 ± 46.01
.79 ± 0.44 9.49 ± 0.66 9.48 ± 0.38
.48 ± 0.27 2.23 ± 0.27 1.88 ± 0.19
ained stable between the 2ndday and7th day after treatment initiation (p N 0.05, one-way
in the blood at the same time points (p N 0.05 Paired-Samples T Test). Eight samples were
95T. Li et al. / Journal of the Neurological Sciences 341 (2014) 88–96study, an increasing tendencywas observed. Itwas anticipated that a sig-
niﬁcant change in IL-10 might be observed if the treatment was extend-
ed. By combining our data with known information, it was suggested
that there was a correlation between the anti-inﬂammatory modulation
induced by atorvastatin and the shrinkage of the SDH volume.
Actually, it has been known that modulation of inﬂammation is re-
lated to both the angiogenesis and the permeability of vessels. TNF-α,
one of themost potent pro-inﬂammatory factors, regulated vascular en-
dothelial cell permeability through formation of stress ﬁber and inter-
ruption of cellular junctions, which could be conﬁrmed further by
using transendothelial electrical resistance (TER) [37–40]. IL-6 promot-
ed permeability of vessels by expanding endothelium interspace [41].
Since high permeability of vessels was detected in the neomembrane
of CSDH [18,42–46], the correlation between the level change in both
IL-6 and TNF-α and the formation and elimination of SDH strongly indi-
cated that these cytokines played a critical role in repair of vascular per-
meability. However, to conﬁrm this hypothesis, it will be essential to
carry out a research in future.
Furthermore, it has been acknowledged that atorvastatin possesses
dual functions, i.e., regulating inﬂammatory reaction and promoting an-
giogenesis. Matsumura has concluded that low doses of atorvastatin
could enhance expression of VEGF in rats’ ischemic hindlimbs [47]. In
this study, the MVD marked by CD31 was enhanced by atorvastatin,
which was also correlated with the change in TNF-α and IL-6. Conse-
quently, the role the angiogenesis along with the inﬂammation played
in the formation and elimination of SDH was apparent. However, it
has been known that excessive expression of VEGF could not only lead
to more blood vessels with high permeability [48] but also result in im-
mature and unstable vessels, whichwould not beneﬁt the absorption of
hematomas [49]. In this study, it was observed that the gene of VEGF
markedly increased and then showed a descendant tendency in the
atorvastatin group. On the contrary, the gene of VEGF in saline group
showed an ascent tendency. Then, we could make a hypothesis that
the maturity of blood vessels would also participate in the absorption
of hematoma. Meanwhile, a future research should be performed to
conﬁrm this hypothesis.
Our study was only designed to observe the change in inﬂammatory
cytokines in the formation and absorption of SDH. The SDH model could
not ideally mimic the chronic course of the CSDH. The reason for this is
that the outcome had only been observed for 1 week. Thus, to conﬁrm
the role that the inﬂammation plays in CSDH, more detailed data and a
modiﬁed SDH model should be provided in the future. Since there is a
clear clue to imply the role of both angiogenesis and inﬂammation in
CSDH, it is necessary to ﬁnd out which one is the initial role and whether
both of themwork simultaneously in the same process. However, a ther-
apeutic strategy based on atorvastatin for CSDH is potentially suggested.5. Conclusion
In summary, based on SDH models in vivo, we conﬁrmed that ator-
vastatin (3 mg/kg/day) could not only modulate the inﬂammatory cy-
tokines but also promote the shrinkage of SDH as well as improve
neural functions of the SDH rats. The therapeutic results of atorvastatin
treatmentmight be partially ascribed to normalization of the inﬂamma-
tory reaction and enhancement in potential angiogenesis.Conﬂict of interest
None.Acknowledgments
We acknowledge Weiyun Cui, Fanglian Chen and Lei Zhou for their
assistancewith technical aspects of experiments and data interpretation.References
[1] Bullock MR, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell DW, et al. Surgical man-
agement of acute subdural hematomas. Neurosurgery 2006;58:S16–24 [discussion
Si-iv].
[2] Seelig JM, Becker DP, Miller JD, Greenberg RP, Ward JD, Choi SC. Traumatic acute
subdural hematoma: major mortality reduction in comatose patients treated within
four hours. N Engl J Med 1981;304:1511–8.
[3] Wilberger JE, Harris M, Diamond DL. Acute subdural hematoma: morbidity, mortal-
ity, and operative timing. J Neurosurg 1991;74:212–8.
[4] Weigel R, Schmiedek P, Krauss JK. Outcome of contemporary surgery for chronic
subdural haematoma: evidence based review. J Neurol Neurosurg Psychiatry
2003;74:937–43.
[5] Schachenmayr W, Friede RL. The origin of subdural neomembranes. I. Fine structure
of the dura-arachnoid interface in man. Am J Pathol 1978;92:53–68.
[6] Moskala M, Goscinski I, Kaluza J, Polak J, Krupa M, Adamek D, et al. Morphological
aspects of the traumatic chronic subdural hematoma capsule: SEM studies. Microsc
Microanal 2007;13:211–9.
[7] Yamashima T, Yamamoto S. The origin of inner membranes in chronic subdural
hematomas. Acta Neuropathol 1985;67:219–25.
[8] Suzuki M, Endo S, Inada K, Kudo A, Kitakami A, Kuroda K, et al. Inﬂammatory cyto-
kines locally elevated in chronic subdural haematoma. Acta Neurochir
1998;140:51–5.
[9] Delgado-Lopez PD, Martin-Velasco V, Castilla-Diez JM, Rodriguez-Salazar A,
Galacho-Harriero AM, Fernandez-Arconada O. Dexamethasone treatment in chronic
subdural haematoma. Neurocirugia (Astur) 2009;20:346–59.
[10] Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use
of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic
chemotherapy. Br J Cancer 2006;94:1011–5.
[11] Dimmeler S, Aicher A, VasaM, Mildner-Rihm C, Adler K, TiemannM, et al. HMG-CoA
reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-
kinase/Akt pathway. J Clin Invest 2001;108:391–7.
[12] Jain MK, Ridker PM. Anti-inﬂammatory effects of statins: clinical evidence and basic
mechanisms. Nat Rev Drug Discov 2005;4:977–87.
[13] Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, Princen HM, et al. Effect
of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic
lesion progression and inﬂammation in apolipoprotein E*3-Leiden transgenic mice.
Arterioscler Thromb Vasc Biol 2005;25:161–7.
[14] Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, et al.
Rosuvastatin reduces atherosclerosis development beyond and independent of its
plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence
for antiinﬂammatory effects of rosuvastatin. Circulation 2003;108:1368–74.
[15] Wang D, Jiang R, Liu L, Dong JF, Zhang JN. Membrane neovascularization and drain-
age of subdural hematoma in a rat model. J Neurotrauma 2010;27:1489–98.
[16] Hessler RB, Kfoury H, Al-Watban J, Hassounah M. Angiomatous pleomorphic
xanthoastrocytoma as a component of ganglioglioma. Ann Saudi Med 1999;19:
48–51.
[17] Labadie EL, Glover D. Chronic subdural hematoma: concepts of physiopathogenesis.
A review. Can J Neurol Sci 1974;1:222–5.
[18] Watanabe S, Shimada H, Ishii S. Production of clinical form of chronic subdural
hematoma in experimental animals. J Neurosurg 1972;37:552–61.
[19] Ito H, Saito K, Yamamoto S, Hasegawa T. Tissue-type plasminogen activator in the
chronic subdural hematoma. Surg Neurol 1988;30:175–9.
[20] Kawakami Y, Chikama M, Tamiya T, Shimamura Y. Coagulation and ﬁbrinolysis in
chronic subdural hematoma. Neurosurgery 1989;25:25–9.
[21] Saito K, Ito H, Hasegawa T, Yamamoto S. Plasmin-alpha 2-plasmin inhibitor complex
and alpha 2-plasmin inhibitor in chronic subdural hematoma. J Neurosurg
1989;70:68–72.
[22] Katano H, Kamiya K, Mase M, Tanikawa M, Yamada K. Tissue plasminogen activator
in chronic subdural hematomas as a predictor of recurrence. J Neurosurg
2006;104:79–84.
[23] Shono T, Inamura T, Morioka T, Matsumoto K, Suzuki SO, Ikezaki K, et al. Vascular
endothelial growth factor in chronic subdural haematomas. J Clin Neurosci
2001;8:411–5.
[24] Hohenstein A, Erber R, Schilling L, Weigel R. Increased mRNA expression of
VEGF within the hematoma and imbalance of angiopoietin-1 and -2 mRNA
within the neomembranes of chronic subdural hematoma. J Neurotrauma
2005;22:518–28.
[25] Nanko N, Tanikawa M, Mase M, Fujita M, Tateyama H, Miyati T, et al. Involvement of
hypoxia-inducible factor-1alpha and vascular endothelial growth factor in the
mechanism of development of chronic subdural hematoma. Neurol Med Chir
2009;49:379–85.
[26] Hong HJ, Kim YJ, Yi HJ, Ko Y, Oh SJ, Kim JM. Role of angiogenic growth factors and
inﬂammatory cytokine on recurrence of chronic subdural hematoma. Surg Neurol
2009;71:161–5 [discussion 5–6].
[27] Wada T, Kuroda K, Yoshida Y, Ogasawara K, Ogawa A, Endo S. Local elevation of the
anti-inﬂammatory interleukin-10 in the pathogenesis of chronic subdural hemato-
ma. Neurosurg Rev 2006;29:242–5.
[28] Glover LE, Colgan SP. Hypoxia and metabolic factors that inﬂuence inﬂammatory
bowel disease pathogenesis. Gastroenterology 2011;140:1748–55.
[29] Wang B, Sun L, Tian Y, Li Z, Wei H, Wang D, et al. Effects of atorvastatin in the regu-
lation of circulating EPCs and angiogenesis in traumatic brain injury in rats. J Neurol
Sci 2012;319:117–23.
[30] Araujo FA, Rocha MA, Mendes JB, Andrade SP. Atorvastatin inhibits inﬂammatory
angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1.
Biomed Pharmacother 2010;64:29–34.
96 T. Li et al. / Journal of the Neurological Sciences 341 (2014) 88–96[31] Wang Y, Chang H, Zou J, Jin X, Qi Z. The effect of atorvastatin on mRNA levels of
inﬂammatory genes expression in human peripheral blood lymphocytes by DNA
microarray. Biomed Pharmacother 2011;65:118–22.
[32] Tracey KJ. The inﬂammatory reﬂex. Nature 2002;420:853–9.
[33] Dvorak K, Dvorak B. Role of interleukin-6 in Barrett's esophagus pathogenesis.
World J Gastroenterol 2013;19:2307–12.
[34] Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6
and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte
recruitment seen during acute inﬂammation. Immunity 2001;14:705–14.
[35] FeldmannM, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu
Rev Immunol 1996;14:397–440.
[36] Seymour RM, Henderson B. Pro-inﬂammatory–anti-inﬂammatory cytokine dynam-
ics mediated by cytokine-receptor dynamics in monocytes. IMA J Math Appl Med
Biol 2001;18:159–92.
[37] Petrache I, Birukova A, Ramirez SI, Garcia JG, Verin AD. The role of the microtubules
in tumor necrosis factor-alpha-induced endothelial cell permeability. Am J Respir
Cell Mol Biol 2003;28:574–81.
[38] Kiemer AK,Weber NC, Furst R, Bildner N, Kulhanek-Heinze S, Vollmar AM. Inhibition
of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces
TNF-alpha-induced actin polymerization and endothelial permeability. Circ Res
2002;90:874–81.
[39] Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, et al. Induction of
permeability across endothelial cell monolayers by tumor necrosis factor (TNF)
occurs via a tissue factor-dependent mechanism: relationship between the
procoagulant and permeability effects of TNF. Blood 2002;100:1334–9.[40] Umapathy SN, Kaczmarek E, Fatteh N, Burns N, Lucas R, Stenmark KR, et al. Adeno-
sine A1 receptors promote vasa vasorum endothelial cell barrier integrity via Gi and
Akt-dependent actin cytoskeleton remodeling. PLoS One 2013;8:e59733.
[41] Maruo N, Morita I, Shirao M, Murota S. IL-6 increases endothelial permeability
in vitro. Endocrinology 1992;131:710–4.
[42] Glover D, Labadie EL. Physiopathogenesis of subdural hematomas. Part 2: Inhibition
of growth of experimental hematomas with dexamethasone. J Neurosurg
1976;45:393–7.
[43] Ito H, Yamamoto S, Komai T, Mizukoshi H. Role of local hyperﬁbrinolysis in the
etiology of chronic subdural hematoma. J Neurosurg 1976;45:26–31.
[44] Labadie EL, Glover D. Physiopathogenesis of subdural hematomas. Part 1: Histolog-
ical and biochemical comparisons of subcutaneous hematoma in rats with subdural
hematoma in man. J Neurosurg 1976;45:382–92.
[45] Sato S, Suzuki J. Ultrastructural observations of the capsule of chronic subdural
hematoma in various clinical stages. J Neurosurg 1975;43:569–78.
[46] Yamashima T, Yamamoto S, Friede RL. The role of endothelial gap junctions in the
enlargement of chronic subdural hematomas. J Neurosurg 1983;59:298–303.
[47] Matsumura M, Fukuda N, Kobayashi N, Umezawa H, Takasaka A, Matsumoto T, et al.
Effects of atorvastatin on angiogenesis in hindlimb ischemia and endothelial progen-
itor cell formation in rats. J Atheroscler Thromb 2009;16:319–26.
[48] Tsigkos S, Koutsilieris M, Papapetropoulos A. Angiopoietins in angiogenesis and be-
yond. Expert Opin Investig Drugs 2003;12:933–41.
[49] Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-speciﬁc
growth factors and blood vessel formation. Nature 2000;407:242–8.
